Evidence Suggesting That Obesity Prevention Measures May Improve Prostate Cancer Outcomes Using Data from a Prospective Randomized Trial

Abstract EN

Purpose.

Increasing body mass index (BMI) is associated with higher risk prostate cancer (PC) at presentation.

Whether increasing BMI also prompts earlier salvage androgen suppression therapy (sAST) is unknown.

Materials and Methods.

Between 1995 and 2001, 206 men with unfavorable risk PC were treated with radiation therapy (RT) or RT and six months of androgen suppression therapy in a randomized controlled trial (RCT).

108 sustained PSA failure; 51 received sAST for PSA approaching 10 ng/mL; 49 with BMI data comprised the study cohort.

A multivariable Cox regression analysis identified pretreatment factors associated with earlier sAST receipt.

Results.

Increasing BMI prompted earlier sAST (median years: 3.7 for overweight/obese, 6.9 for normal weight; adjusted hazard ratio (AHR): 1.11; 95% CI: 1.04, 1.18; P=0.002) as did high versus other risk PC (median: 3.2 versus 5.2 years; AHR: 2.01; 95% CI: 1.05, 3.83; P=0.03).

Increasing median time to sAST was observed for overweight/obese men with high versus other risk PC and for normal-weight men with any risk PC being 2.3, 4.6, and 6.9 years, respectively (P<0.001 for trend).

Conclusion.

Increasing BMI was associated with earlier sAST.

A RCT evaluating whether BMI reduction delays or eliminates need for sAST is warranted.